Skip to main content

Journal Club

Spine

Spine Oncology – Primary Spine Tumors

Neurosurgery | 2017

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1093/neuros/nyw064

PMID

N/A

PICO

Population

Patients with primary osseous spinal tumors such as chordoma, chondrosarcoma, giant cell tumor, osteoid osteoma, and other less common spine neoplasms.

Intervention

Multidisciplinary primary spine tumor management including en bloc resection when feasible, selected intralesional surgery, radiation, and newer adjunctive systemic or ablative therapies.

Comparator

Less oncologically rigorous surgery, historical piecemeal resection, or nonoperative management depending on tumor biology and resectability.

Outcomes

Local control, recurrence risk, survival, pain relief, neurologic preservation, and treatment-related morbidity.

Design

Type

Narrative review

Randomized

No

Multicenter

N/A

Blinded

N/A

Follow-up

N/A

Primary endpoint

Synthesis of evidence on multidisciplinary management approaches

Secondary endpoints

  • Local recurrence rates
  • Median survival
  • Treatment morbidity and quality of life

Practice impact

What this means

Primary spine tumors require multidisciplinary management at specialized centers. En bloc resection with appropriate margins (Enneking principles) remains standard for most tumors, associated with better local control and survival. Emerging options include denosumab for GCTs, percutaneous ablation for osteoid osteomas, and advanced radiation techniques for chordomas. Treatment decisions must balance oncologic control with morbidity and quality of life.

Bottom line

Multidisciplinary management with Enneking-appropriate surgical resection remains cornerstone for primary spine tumors, but emerging medical, percutaneous, and radiation therapies offer promising adjuncts or alternatives in select cases.

Strength of evidence

moderate

Recommendation

consider change

Why it matters

  • Enneking-appropriate resection consistently associated with better local control and survival across tumor types p. 2
  • Denosumab shows promise for giant cell tumors to facilitate surgery or avoid it p. 3
  • Advanced radiation techniques (proton, carbon ion) may offer alternatives for unresectable tumors p. 4

What would change my mind

  • A validated full-text appraisal with explicit effect estimates and page-linked citations.

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

This is a narrative review rather than a systematic evidence synthesis, so recommendations reflect expert interpretation of heterogeneous retrospective literature.

Confounding

The source studies vary widely by tumor histology, surgical margins, radiation strategy, and referral-center case mix, which limits clean comparison across treatment approaches.

Missing data

Outcome completeness is determined by the individual series cited in the review and is not standardized across the summarized evidence base.

Multiplicity

The review discusses many tumor-specific endpoints without a unified statistical testing plan, so effect estimates are best treated as context-setting rather than definitive.

Notes

  • The strongest quantitative signals come from retrospective margin-control series, not randomized primary spine tumor trials.

Stats check

NNT

N/A

Effect sizes

  • Osteosarcoma: Enneking-appropriate resection associated with lower local recurrence (10% vs 44%) and increased median survival (6.8 vs 3.7 years) p. 2
  • Chordoma: Enneking-appropriate resection associated with lower local recurrence (16% vs 46%) and increased median survival (8.4 vs 6.4 years) p. 2
  • Chondrosarcoma: Enneking-appropriate resection associated with lower recurrence (HR 2.09) p. 2

Absolute effects

  • Aneurysmal bone cysts: 0% local recurrence after Enneking-appropriate resection vs 12% after intralesional resection p. 2
  • Chordoma: 21% of cases where en bloc resection with marginal/wide margins not possible p. 4
  • Surgical adverse events: Up to 100% for sacral lesions, 74% for mobile spine tumors p. 5

Concerns

  • Most cited studies are retrospective with potential selection bias
  • Hazard ratios provided without confidence intervals
  • Follow-up durations variable and sometimes short (e.g., 3 years for some studies)

External validity

Who it applies to

Patients similar to the study population once inclusion criteria are verified.

Who it does not

Patients outside the verified eligibility criteria.

Generalizability notes

  • External validity depends on operative workflow, center expertise, and patient selection.

Evidence trace

Source trace and metadata

Citations (5)

claim_id

methods_critique.risk_of_bias

locator

p. 1-7

claim_id

methods_critique.risk_of_bias

locator

p. 2

quote

respecting Enneking principles results in lower LR rates and increased median survival for both osteosarcomas (LR: 10% vs 44%; MS: 6.8 vs 3.7 yr)

claim_id

methods_critique.risk_of_bias

locator

p. 3

quote

Denosumab...has been correlated with good disease control and allows for less morbid surgery and may even allow the avoidance of surgery in some cases

claim_id

stats_check.concerns

locator

p. 1

claim_id

practice_impact.bottom_line

locator

p. 1

Metadata

Generated at

2026-03-09T22:35:59.340Z

Version

pdf-archive-ingest-v1